leadf
logo-loader
viewPDS Biotechnology Corporation

Full interview: PDS Biotech preparing to initiate three phase two clinical studies for lead candidate PDS0101 in partnership with leading oncology institutions

PDS Biotechnology (NASDAQ-PDSB) CEO Frank Bedu-Addo sat down with Steve Darling from Proactive in New York to discuss the company that had an unexpected discovery that positively charged cationic lipids, being studied in the unrelated field of gene therapy.

Bedu-Addo telling Proactive where their products are in the pipeline and also about some of the clinical studies that are underway and about to begin. 

Quick facts: PDS Biotechnology Corporation

Price: 2.18 USD

NASDAQ:PDSB
Market: NASDAQ
Market Cap: $48.53 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Lotus Resources reveals highlights on scoping study at its Kayelekera...

Lotus Resources Ltd (ASX:LOT) Managing Director Eduard Smirnov tells Proactive the group's Kayelekera Uranium Project can be among first uranium projects to begin production to meet the impending uranium supply shortfall. Smirnov says according to the study, the project will have a long mine...

5 hours, 36 minutes ago

2 min read